Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations

Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations

The oncogenic role and clinical relevance of <i>BRCA</i> mutations in NSCLC remain unclear. We aim to evaluate the characteristics and clinical outcomes of patients with NSCLC harboring <i>BRCA</i> mutations treated at Hadassah Medical Center (HMC). We retrospectively assesse...

Full description

Bibliographic Details
Main Authors: Johnathan Arnon, Michael Tabi, Yakir Rottenberg, Aviad Zick, Philip Blumenfeld, Tamar Hamburger, Eli Pikarsky, Eti Avraham, Leeby Levine, Aron Popovtzer, Tamar Yablonski-Peretz, Luna Kadouri, Hovav Nechushtan
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Cancers
Subjects:
nonsmall cell lung cancer (NSCLC)
BRCA
platinum chemotherapy
poly (adenosine-phosphate-ribose) polymerase inhibitors (PARPi)
Online Access:https://www.mdpi.com/2072-6694/15/19/4733

Internet

https://www.mdpi.com/2072-6694/15/19/4733

Similar Items